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& Abstract
Objectives: Compare healthcare resource utilization (HCRU)
and costs between patients prescribed opioids (RxOP) and
those who were not (NoRxOP) during an emergency depart-
ment (ED) or inpatient visit.
Methods: Retrospective cohort analysis was performed (Jan-
uary 2006 to September 2010). Continuously eligible RxOP
patients in ED/inpatient settings (January 2007 to September
2009) were included if age was ≥ 12 years by initial prescrip-
tion date (or random date between first ED/inpatient admis-
sion and September 30, 2009 [NoRxOP patients]).
Healthcare resource utilization and costs for 12 months
after initial prescription were compared. Univariate descrip-
tive analyses were performed for baseline and outcome
variables and compared using appropriate tests. Risk adjust-
ment compared HCRU between RxOP and NoRxOP cohorts
for the postindex period.
Results: Of 27,599 eligible patients, RxOP patients
(n = 18,819) were younger, less likely to be male, more likely
to reside in southern United States and to have Preferred
Provider Organization health plans, and had lower comor-
bidity index scores, compared with NoRxOP patients
(n = 8,780). RxOP patients were less likely to have nonpain-
related comorbidities and more frequently diagnosed with
pain-related comorbidities.
Unmatched and propensity-matched RxOP patients expe-
rienced higher HCRU and costs in all subcategories (total,
inpatient, outpatient ED, physician, pharmacy, other outpa-
tient settings). Opioid abuse frequency was low in patients
with common diagnoses/procedures within 3 months before
initial prescription (0.48%). Average time to abuse was
< 1 year (201 days).
Conclusion: Most patients were prescribed opioids initially
during ED/inpatient visits and incurred higher HCRU than
those not prescribed opioids. Among those with diagnosed
opioid abuse after initiating opioids, time to diagnosis was
rapid (range: 14 to 260 days) for patients with common
diseases and procedures. &
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INTRODUCTION
Over the past 2 decades, health professionals have been
addressing the issue of undertreated pain more aggres-
sively through the increase in prescription opioids to
treat cancer-related and noncancer pain. This has
resulted in a simultaneous increase in opioid abuse in
the United States.1,2 The doses at which opioid analge-
sics are sometimes abused can lead to respiratory
depression and death.3 In 2009, there were over 2 mil-
lion opioid-dependent adults in the United States, and
opioid misuse has become a leading cause of death
nationwide.4 According to the Substance Abuse and
Mental Health Services Administration (SAMHSA) in
2009, there were 35 emergency department (ED) visits,
161 patient reports of drug abuse or dependence, and
461 reports of nonmedical uses of opioid analgesics for
every unintentional opioid-related overdose death.5
Use of prescription opioids in the United States
increased 402% overall from 1997 to 2007,6 and in
the medically insured population, 7 to 8 patients per
10,000 have shown evidence of diagnosed opioid
abuse.7 Additionally, diagnosed abusers with multiple
comorbidities incurred healthcare expenses which were
8 times higher than those without diagnosed abuse.8
Patients with diagnosed opioid abuse were 6.7 times
more likely to be hospitalized and 2.3 times more likely
to have ED visits.9
Researchers are becoming increasingly aware of the
instrumental role that ED settings play in the prescrip-
tion of opioid medications. EDs prescribe 29% of all
opioid medications administered and are the largest
ambulatory source for opioids.10 Inappropriate pre-
scribing of opioid medications in the ED setting can
occur and includes the prescription of long-acting
opioids to treatment-naive individuals.11 EDs also often
handle the consequences of inappropriate prescription
opioid use. An estimated 305,900 ED visits were related
to the nonmedical use of opioid analgesics in 2008, a
111% increase from the 144,600 visits in 2004.12
However, while EDs have been well studied in the
distribution of American opioid medications,8–10 few
studies differentiate between inpatient and ED settings.
Research focused on the factors associatedwith prescrib-
ing opioidmedications inUnited States inpatient hospital
settings has revealed variation in demography and
hospital location. According to a retrospective study
conducted by Olsen et al.13, those living in the northeast
(OR = 0.60; 95% CI [0.52 to 0.69]) or Midwest (OR =
0.75; 95%CI [0.66 to 0.85]), aswell asHispanic patients
(OR = 0.67; 95% CI [0.56 to 0.81]) and those of other
races (OR = 0.68; 95% CI [0.52 to 0.90]), had lower
odds of receiving a prescription opioid. The Joint
Commission on Accreditation of Healthcare Organiza-
tions (JCAHO) asserted that opioid use is generally safe
for most patients, but the risk of problems like abuse
warranted suggested actions for inpatient hospital set-
tings, such as monitoring patients properly, tracking and
analyzing opioid-related incidents, screening patients for
risk factors for abuse, and building electronic alert
systems for opioiddosing limits inprescription systems.14
In this study, healthcare resource utilization (HCRU)
and costs between patients who were prescribed opioids
vs. those without an opioid prescription during an ED or
inpatient visit were compared. Additionally, the rate of
diagnosed opioid abuse by specific diseases and proce-
dures was determined after the first opioid prescription.
METHODS
Data Source and Study Sample
A retrospective cohort analysis was performed using
data from the linked MarketScan Commercial Claims
and Encounters, Medicare Supplemental, and Hospital
Drug Databases (including medical and pharmacy
claims) between January 2006 and September 2010,
with an identification period from January 1, 2007
through September 30, 2009.
The index date was defined as the date of the initial
opioid prescription for the prescription opioid user
(RxOP) cohort and the random date between the first
ED/inpatient admission and the end of the identification
period for those not prescribed opioids in an ED/
inpatient setting (NoRxOP cohort).
Baseline variables were calculated during the
12 months prior to the index date, otherwise known
as the pre-index period, and outcome variables were
calculated during the 12 months after the index date (ie,
postindex period).
Patients who were 12 years of age or older on the
index date with continuous health plan enrollment,
including medical and pharmacy benefits, from the pre-
index period through the postindex period were
selected. Subjects were excluded from the study if they
were prescribed opioid medications during the
12-month pre-index period.
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Cohort Assignments
In addition to the comparison between RxOP and
NoRxOP patients, the diagnosed opioid abuse after
prescription cohort was created using a population of
patients diagnosed with certain diseasesa or who had
certain proceduresb during the 3 months preceding the
first opioid prescription in an emergency room
(ER)/inpatient setting during the identification period.
Qualified participants were required to be identified as
diagnosedopioid abusers if they had evidence of diagnosis
of opioid abuse after the first opioid prescription date.
Opioid abuse was defined as a new diagnosis for opioid
type dependence (International Classification of Disease
9th Revision Clinical Modification [ICD-9-CM:
304.0X]), combinations of opioid abuse with any other
[304.7X] (opioid abuse [305.5X], or poisoning by opiates
and related narcotics, not including heroin [965.00,
965.02, 965.09]).
Covariates
Baseline demographic variables included age, age group
(12 to 17, 18 to 25, 26 to 34, 35 to 54, 55 to 64, 65+
years), gender, geographic region (Northeast, North
Central, South, West, Unknown), and insurance type
(Exclusive Provider Organization, Health Maintenance
Organization, Point of Service, Preferred Provider
Organization, Other).
Baseline comorbidity measures included an index
based on a comprehensive set of 30 ICD-9-CM
comorbidity flags called the Elixhauser Index score,15
with a cut point of at least 2. The average pre-index
Quan-Charlson Comorbidity Index (CCI) score was
calculated as a weighted summation of 22 comorbid
conditions plus warfarin use.16 Pre-index Chronic
Disease Score (CDS)17 values based on current medi-
cation use (ie, pharmacy claims data) were utilized as
well. These 3 comorbidity indices provided an estima-
tion of different aspects of the patients’ health status,
with higher index scores indicating worse health status.
Pre-index pain-related comorbid conditions included
low back pain, other back/neck disorders, arthritis,
neuropathic pain, headache/migraine, fibromyalgia,
and cancer. Pre-index nonpain-related comorbid con-
ditions included other substance abuse, nonopioid
poisoning, psychiatric disorders, human immunodefi-
ciency virus (HIV)/acquired immune deficiency syn-
drome (AIDS), endocarditis, skin infections/abscesses,
gastrointestinal bleeding, cirrhosis/chronic/acute liver
disease, hepatitis A, B, or C, alcoholic hepatitis, other
hepatitis, pancreatitis, sexually transmitted disease,
herpes simplex, burns, and trauma.
Total pre-index healthcare costs, along with inpa-
tient, outpatient ED, physician visit, other outpatient,
and pharmacy costs, were calculated and adjusted to
June 2010 US dollars using the Consumer Price Index
(CPI) medical care component. Pre-index HCRU mea-
sures included the number of inpatient, outpatient ED,
and physician office visits as well as binary indicators of
having at least one visit.
Top 10 conditions or procedures prior to opioid abuse
have been grouped into different categories: cardiovas-
cular/metabolic conditions (hypertension not otherwise
specified (NOS); benign hypertension; uncontrolled type
II diabetes mellitus; hyperlipidemia; coronary athero-
sclerosis); mental health (depressive disorder); general
health/routine screening (malaise and fatigue; routine
gynecologic examination, mammogram); opioid-related
conditions (opioid dependence—continuous, opioid
dependence—unspecified, opioid poisoning); and pain
conditions (lumbago, pain in limb, abdominal pain
unspecified site, chest pain). Procedures prior to opi-
oid abuse included cardiac procedures (percutaneous
transluminal coronary angioplasty or coronary athero-
sclerosis, left heart cardiac catheterization, coronary
arteriogram-2 catheterization, left heart angiocardio-
gram, noncoronary angiogram), orthopedic procedures
(lymphatic structure biopsy, lumbar/lumbosacral fusion
lateral and posterior, total hip and knee replacements,
refusion of lumbar post), gynecologic surgery (low
cervical c-section, c-section, total abdominal hysterec-
tomy, total abdominal hysterectomy NOS), general
surgery (laparoscopic cholecystectomy), and other pro-
cedures (drug rehabilitation/detoxification).
Outcome Variables
Similar to pre-index costs, total, inpatient, outpatient
ED, physician visit, other outpatient, and pharmacy
costs were calculated during the 12-month follow-up
period based upon the amount paid by the health plan
on relevant claims and net cost of any patient contribu-
tion (eg, copayment). Costs were expressed in 2010 U.S.
dollars and were adjusted using the medical care
aCardiovascular/metabolic conditions, mental health, general
health/routine screening, opioid-related conditions, pain conditions.
bCardiac procedure, orthopedic procedures, gynecologic surgery,
general surgery, others.
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component of the U.S. CPI. Postindex HCRU included
the number of inpatient, outpatient ED, and physician
office visits, plus binary indicators of having at least one
visit.
The frequency of diagnosed opioid abuse was defined
as the number of patients detected with certain diseasesc
or procedures (Table 4) in the 3 months prior to the
index date (first opioid prescription date in ED/inpa-
tient), number of diagnosed opioid abusers after index
date, and number of days from first opioid prescription
to first opioid abuse diagnosis.
Statistical Analysis
Univariate descriptive analyses were performed for all
baseline and outcome variables. Percentages and
standard deviations were calculated for dichotomous
variables, and P values were calculated using the chi-
squared test. Means and standard deviations were
calculated for continuous variables, and P values were
calculated using the student’s t-test.
To adjust the baseline differences in demographic and
clinical characteristics between the 2 cohorts, risk
adjustment was performed using 1:1 propensity score
matching (PSM) to compare all postindex healthcare
costs and utilization between the RxOP and NoRxOP
cohorts. Variables incorporated in matching were
patients’ age, gender, geographic region, health plan
type, comorbidities, HCRUs, and costs in the pre-index
period. The PSM method created very closely balanced
study cohorts that appeared similar on a large number of
measures. In essence, the PSM methodology sought to
mimic a randomized experiment by constructing a
control group under the assumption of the ignorable
treatment assignment, that is, individuals were ran-
domly assigned to treatment and control groups, given a
set of observed covariates. The propensity score mod-
eled the clinical decision-making process; patients were
matched if their propensity scores were within 0.01
units of each other.
Multivariate analysis was performed by using gener-
alized linear models, where log link and gamma distri-
butions were used for cost outcomes, negative binomial
distribution was used for count variables such as
number of healthcare utilization visits, and logistic link
was used for binary outcomes such as having at least one
visit.
RESULTS
Study Sample
After applying inclusion and exclusion criteria, a total of
27,599 patients were eligible for the study (Figure 1).
Sixty-eight percent of the patients (RxOP; n = 18,819)
were prescribed opioids (mean age = 54.5 years), and
32% (NoRxOP; n = 8,780) were not (mean
age = 55.1 years). Among RxOP patients (n = 18,819),
17% (n = 3,226) were prescribed opioids in the ED
setting, and83%(n = 15,593)wereprescribedopioids in
inpatient settings. However, among all patients observed
in the sample with an ER visit, 56% were prescribed
opioids. Among all observed patients with an inpatient
admission, 71% were prescribed opioids.
Among patients in the RxOP cohort, the majority of
patients (96%, n = 18,031) were prescribed immediate-
release opioids, and 4% (n = 788) were prescribed
extended-release opioids. Among all patients who were
prescribed an opioid (N = 18,819), the long-acting
opioid prescription rate was slightly higher in the ED
(6.5%) vs. inpatient setting (3.7%).
Demographics and Clinical Characteristics
RxOP patients were younger (54.5 vs. 55.1;
P = 0.0293), less likely to be male (35.6% vs. 43.0%;
P < 0.0001), more likely to reside in the southern region
of the United States (86.6% vs. 78.2%; P < 0.0001),
and more likely to have a PPO health plan (55.1% vs.
49.8%; P < 0.0001) compared with NoRxOP patients
(Table 1).
Additionally, RxOP patients were less likely to have
Elixhauser Index scores of at least 2% (18.5% vs.
Total Patients 
(N=27,599)
68%  Prescribed Opioid  
(N=18,819)
96% Prescribed 
Short Acting 
Opioid (N=18,031)
4% Prescribed 
Long Acting Opioid 
(N=788)
32%  Not Prescribed Opioid
(N=8,780)
Figure 1. Patient selection.
cCardiovascular/metabolic conditions, mental health, general
health/routine screening, opioid-related conditions, pain conditions.
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19.5%; P = 0.0430) and had lower CCI (1.10 vs. 1.31;
P < 0.0001) and CDS scores (4.54 vs. 4.88; P < 0.0001)
than NoRxOP patients.
RxOP patients were less likely to have many of the
nonpain-related comorbid conditions studied, including
other substance abuse (2.6% vs. 4.4%; P < 0.0001),
nonopioid poisoning (0.8% vs. 1.7%; P < 0.0001),
psychiatric disorders (13.8% vs. 17.6%; P < 0.0001),
endocarditis (0.2% vs. 0.4%; P = 0.0040), gastrointes-
tinal bleeding (11.8% vs. 13.0%; P = 0.0044), cirrhosis/
chronicoracute liverdisease (2.9%vs.3.7%,P=0.0004),
alcoholic hepatitis (0.1% vs. 0.2%; P = 0.0012), and
pancreatitis (0.9% vs. 1.6%, P < 0.0001). Exceptions
included sexually transmitted diseases (6.8% vs. 5.7%;
Table 1. Demographic and Clinical Characteristics of Patients Prescribed and Not Prescribed Opioid Medications
Baseline Demographic Conditions
Prescription Opioid
Patients (N = 18,819)
Patients Not Prescribed
Opioids (N = 8,780)
P Value Effect SizeN/Mean %/STD N/Mean %/STD
Age (mean) 54.54 17.62 55.08 19.69 0.0293 2.87
12 to 17 257 1.37% 241 2.74% < 0.0001 9.73
18 to 25 582 3.09% 370 4.21% < 0.0001 5.98
26 to 34 2,306 12.25% 1,143 13.02% 0.0736 2.30
35 to 54 5,616 29.84% 2,242 25.54% < 0.0001 9.64
55 to 64 4,575 24.31% 1,900 21.64% < 0.0001 6.35
65+ 5,483 29.14% 2,884 32.85% < 0.0001 8.03
Gender (male) 6,690 35.55% 3,779 43.04% < 0.0001 15.38
Geographic region
Northeast 396 2.10% 224 2.55% 0.0196 2.96
North Central 1,752 9.31% 1,468 16.72% < 0.0001 22.16
South 16,287 86.55% 6,867 78.21% < 0.0001 22.00
West 346 1.84% 209 2.38% 0.0028 3.77
Insurance plan type
HMO 2,358 12.53% 1,215 13.84% 0.0026 3.87
PPO 10,375 55.13% 4,372 49.79% < 0.0001 10.70
Other 3,388 18.00% 1,876 21.37% < 0.0001 8.47
Baseline comorbid conditions
Elixhauser Index (≥ 2%) 3,473 18.45% 1,710 19.48% 0.0430 2.61
Charlson Comorbidity Index (CCI) score 1.10 1.73 1.31 1.88 < 0.0001 11.63
Chronic disease score 4.54 3.96 4.88 4.06 < 0.0001 8.43
Nonpain-related comorbid condition
Other substance abuse 490 2.60% 385 4.38% < 0.0001 9.71
Nonopioid poisoning 159 0.84% 145 1.65% < 0.0001 7.27
Psychiatric disorders 2,596 13.79% 1,547 17.62% < 0.0001 10.53
Endocarditis 45 0.24% 39 0.44% 0.0040 3.51
Gastrointestinal bleed 2,217 11.78% 1,140 12.98% 0.0044 3.65
Cirrhosis/chronic or acute liver disease 548 2.91% 326 3.71% 0.0004 4.48
Alcoholic hepatitis 9 0.05% 15 0.17% 0.0012 3.72
Pancreatitis 166 0.88% 143 1.63% < 0.0001 6.71
Sexually transmitted disease 1,277 6.79% 496 5.65% 0.0003 4.71
Trauma 4,217 22.41% 1,866 21.25% 0.0310 2.80
Pain-related Comorbid Conditions
Cancer 2,275 12.09% 945 10.76% 0.0014 4.17
Low back pain 4,467 23.74% 1,525 17.37% < 0.0001 15.81
Other back/neck disorders 4,102 21.80% 1,426 16.24% < 0.0001 14.19
Arthritis 8,011 42.57% 3,123 35.57% < 0.0001 14.38
Neuropathic pain 2,005 10.65% 846 9.64% 0.0096 3.37
Fibromyalgia 601 3.19% 193 2.20% < 0.0001 6.15
Baseline healthcare utilization
Patients with inpatient visits 3,440 18.28% 6,866 78.20% < 0.0001 149.83
Patients with outpatient ED visits 6,798 36.12% 4,153 47.30% < 0.0001 22.81
Patients with outpatient physician visits 17,931 95.28% 8,240 93.85% < 0.0001 6.32
Number of inpatient visits 0.26 0.70 0.98 0.82 < 0.0001 94.07
Number of outpatient ED visits 0.68 1.55 0.84 1.39 < 0.0001 10.41
Number of outpatient Physician visits 9.03 7.40 8.44 7.26 < 0.0001 8.01
Baseline healthcare costs
Total costs $17,120 $36,837 $25,569 $41,535 < 0.0001 21.52
Inpatient costs $4,462 $21,813 $13,131 $28,211 < 0.0001 34.38
Outpatient physician visit costs $832 $749 $760 $704 < 0.0001 9.87
STD, standard deviation; EPO, exclusive provider organization; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; ED, emergency
department.
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P = 0.0003) and trauma (22.4% vs. 21.3%;
P = 0.0310).
While RxOP patients were generally less likely to
have nonpain-related comorbid conditions, they were
more often found with every pain-related comorbid
condition studied (Table 1). Common conditions
included arthritis (42.6% vs. 35.6%; P < 0.0001), low
back pain (23.7% vs. 17.4%; P < 0.0001), other back/
neck disorders (21.8% vs. 16.2%; P < 0.0001), and
cancer (12.1% vs. 10.8%; P = 0.0014).
Baseline Costs and Utilization
RxOP patients were less likely to have inpatient (18.3%
vs. 78.2%; P < 0.0001) and ED visits (36.1% vs.
47.3%; P < 0.0001), but more likely to have physician
visits (95.3% vs. 93.9%; P < 0.0001) in the pre-index
period. Correspondingly, RxOP patients had a lower
number of average inpatient (0.26 vs. 0.98; P < 0.0001)
and ED visits (0.68 vs. 0.84; P < 0.0001) but greater
physician visits (9.03 vs. 8.44; P < 0.0001).
RxOP patients had lower total ($17,120 vs. $25,569;
P < 0.0001) and inpatient costs ($4,462 vs. $13,131;
P < 0.0001) but higher outpatient physician visit costs
than NoRxOP patients ($832 vs. $760; P < 0.0001).
Postindex Descriptive Outcomes
In the unmatched cohorts, it was more common for
RxOP patients to have inpatient (100% vs. 23.1%,
P < 0.0001), outpatient ED (45.2% vs. 29.8%; P <
0.0001), and physician visits (93.4% vs. 90.2%;
P < 0.0001), and RxOP patients utilized more of these
2 types of visits compared with NoRxOP patients
(Table 2). RxOP patients also had higher average
healthcare costs in all subcategories, including total
($42,829 vs. $16,861; P < 0.0001), inpatient ($26,484
vs. $5,199; P < 0.0001), outpatient ED ($520 vs. $360;
P < 0.0001), andphysician visit costs ($833 vs. $682;P<
0.0001), pharmacy ($3,042 vs. $2,898;P = 0.0406), and
other outpatient costs ($11,954 vs. $7,722; P < 0.0001).
Postindex-Adjusted Outcomes
After PS matching and controlling for baseline demo-
graphic and clinical differences using the generalized
linear model, results were slightly different in magnitude
from the unadjusted values but did not change the
postindex descriptive healthcare cost and utilization
pattern, as illustrated in Figure 2. Demographic and
clinical results of RxOP andNoRxOP cohorts after PSM
are outlined in Table 3. After matching, no demographic
or clinical variable differed significantly between the 2
cohorts. Among the 5,099 matched pairs, the RxOP
cohort had more inpatient (1.58 vs. 0.36; P < 0.0001),
physician office (10.17 vs. 8.96; P < 0.0001), and ED
visits (1.12 vs. 0.67;P < 0.0001) thanmatchedNoRxOP
patients in the follow-up period.
RxOP users had significantly higher healthcare costs
in terms of total healthcare ($49,766 vs. $19,875;
P < 0.0001), inpatient ($30,659 vs. $6,104; P <
0.0001), outpatient ED ($627 vs. $408; P < 0.0001),
outpatient physician visit ($892 vs. $778; P < 0.0001),
outpatient pharmacy ($3,583 vs. $3,199; P = 0.0074),
Table 2. Outcomes Comparison of Patients Prescribed and Not Prescribed Opioid Medications
Prescription Opioid
Patients (N = 18,819)
Not Prescribed Opioid
Patients (N = 8,780)
P Value Effect SizeN/Mean %/STD N/Mean %/STD
Follow-up healthcare utilization
Patients with inpatient visits 18,819 100.00% 2,024 23.05% < 0.0001 257.29
Patients with outpatient ED visits 8,504 45.19% 2,619 29.83% < 0.0001 32.13
Patients with outpatient physician visits 17,583 93.43% 7,919 90.19% < 0.0001 11.83
Number of inpatient visits 1.40 0.95 0.32 0.77 < 0.0001 124.31
Number of outpatient ER visits 0.91 1.80 0.57 1.40 < 0.0001 20.61
Number of outpatient physician visits 9.45 8.41 7.89 7.80 < 0.0001 19.31
Follow-up healthcare cost
Total costs $42,829 $63,927 $16,861 $37,825 < 0.0001 49.44
Inpatient costs $26,484 $45,321 $5,199 $20,955 < 0.0001 60.29
Outpatient ED costs $520 $1,918 $360 $1,379 < 0.0001 9.56
Outpatient physician visit costs $833 $864 $682 $711 < 0.0001 19.02
Outpatient pharmacy costs $3,042 $6,210 $2,898 $4,994 0.0406 2.54
Outpatient other costs $11,954 $32,276 $7,722 $23,487 < 0.0001 14.99
STD, standard deviation; ED, emergency department.
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and other outpatient costs ($14,011 vs. $9,387;
P < 0.001) compared with NoRxOP patients (Figure 3).
Diagnosed Opioid Abuse After Initiation of Prescription
Opioids in ED/Inpatient Setting
Of the total eligible patients, 110 individuals (0.5%)
were diagnosed with opioid abuse after an average of
201 days from their first opioid prescription (Table 4).
By disease, the 7 of 18 patients with opioid-related
conditions (38.9%) were diagnosed with opioid abuse
after an average of 14 days from first opioid prescrip-
tion, followed by mental health conditions (8 of 313, or
2.6%, diagnosed after 201 days), pain conditions (56 of
6,048, or 0.9%, diagnosed after 167 days), cardiovas-
cular/metabolic conditions (43 of 8,969, or 0.5%,
diagnosed after 142 days), and general health/routine
screening (14 of 2,906, or 0.5% diagnosed after
260 days).
By procedure, 5 of 161 patients with cardiac
procedures (3.1%) were diagnosed with opioid abuse
after an average of 167 days. Of those patients with
orthopedic procedures (n = 51), gynecologic surgery
(n = 39), general surgery (n = 26), and others (n = 0),
no diagnosed opioid abuse was detected after the first
opioid prescription.
DISCUSSION
This observational study, using a linked U.S. commer-
cial administrative claims database from 2006 to 2010,
compared healthcare costs and utilization of patients
who initiated prescription opioids vs. those who did not
in ED and inpatient hospital settings.
Results indicated that initial opioid prescribing
remains a common practice in ED and inpatient settings.
In our study, a greater proportion of opioid prescrip-
tions were made in the inpatient hospital setting (71%)
than the ED (56%).
There appears to be an inverse correlation between
baseline clinical characteristics and cost/utilization out-
comes for RxOP and NoRxOP patients. While RxOP
patients have lower comorbidity scores (Elixhauser,
CDS, CCI) when compared with NoRxOP patients,
their postindex healthcare utilization (higher inpatient,
physician office, ED visits) and costs (adjusted total,
outpatient physician visit, outpatient ED, outpatient
pharmacy, other outpatient costs) were higher. How-
ever, after PSM, baseline differences between cohorts
adjusted well. In the postmatch samples, patients in both
cohorts had similar demographic characteristics and
comorbidities. Some previous studies have demon-
strated that certain comorbidities such as depression,
pain, and workers’ compensation status are signifi-
cant risk predictors for high healthcare costs and
utilizations.18,19 In our study, trauma, gastrointestinal
bleeding, and psychiatric disorder were the 3 most
common nonpain-related comorbidities observed during
the baseline period. Arthritis, low back pain, and other
back/neck disorders were the most common pain-related
baseline comorbidities. Although identifying predictors
of high healthcare costs and utilizations were not one of
the objectives in this study, future research will be
necessary to explore the significance of these factors.
1.58
1.12
10.17
0.36
0.67
8.96
0.00
2.00
4.00
6.00
8.00
10.00
12.00
Number of InpaƟent Visits* Number of OutpaƟent ED 
Visits*
Number of OutpaƟent 
Physician Visits*
RxOP Cohort (N=5099)
NoRxOP Cohort (N=5099)
Figure 2. Adjusted utilization among RxOP and NoRxOP cohorts. RxOP, prescription opioid; NoRxOP, no prescription opioid; ED,
emergency department. *P-value < 0.0001.
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Table 3. Baseline Demographic and Clinical Conditions of Patients Prescribed and Not Prescribed Opioid Medications,
After PSM
Baseline Demographic Conditions
Patients Prescribed Opioids
(N = 5,099)
Patients not Prescribed Opioids
(N = 5,099)
P Value Effect SizeN/Mean %/STD N/Mean %/STD
Age (mean) 56.30 18.01 56.84 18.47 0.1309 2.99
12 to 17 98 1.92% 89 1.75% 0.5065 1.32
18 to 25 159 3.12% 156 3.06% 0.8637 0.34
26 to 34 522 10.24% 518 10.16% 0.8959 0.26
35 to 54 1,352 26.52% 1,367 26.81% 0.7369 0.67
55 to 64 1,248 24.48% 1,265 24.81% 0.6961 0.77
65 or older 1,720 33.73% 1,704 33.42% 0.7373 0.66
Gender (male) 2,151 42.18% 2,135 41.87% 0.7482 0.64
Geographic region
Northeast 114 2.24% 118 2.31% 0.7905 0.53
North Central 621 12.18% 582 11.41% 0.2312 2.37
South 4,251 83.37% 4,296 84.25% 0.2264 2.40
West 107 2.10% 94 1.84% 0.3544 1.83
Unknown 6 0.12% 9 0.18% 0.4382 1.54
Insurance plan type
EPO 25 0.49% 16 0.31% 0.1590 2.79
HMO 644 12.63% 637 12.49% 0.8343 0.41
POS 680 13.34% 676 13.26% 0.9071 0.23
PPO 2,756 54.05% 2,758 54.09% 0.9683 0.08
Others 994 19.49% 1,012 19.85% 0.6539 0.89
Baseline comorbid conditions
Elixhauser Index score (≥ 2%) 1,232 24.16% 1,236 24.24% 0.9263 0.18
Charlson Comorbidity Index score 1.49 2.04 1.47 2.03 0.7297 0.68
Chronic Disease score 5.32 4.19 5.28 4.12 0.6132 1.00
Nonpain-related comorbid condition
Other substance abuse 193 3.79% 195 3.82% 0.9175 0.21
Nonopioid poisoning 64 1.26% 79 1.55% 0.2065 2.50
Psychiatric disorders 885 17.36% 874 17.14% 0.7731 0.57
HIV–AIDS 15 0.29% 14 0.27% 0.8525 0.37
Endocarditis 25 0.49% 32 0.63% 0.3525 1.84
Skin infections/abscesses 496 9.73% 468 9.18% 0.3433 1.88
Gastrointestinal bleed 757 14.85% 713 13.98% 0.2148 2.46
Cirrhosis/chronic or acute liver disease 205 4.02% 229 4.49% 0.2391 2.33
Hepatitis A, B, C 33 0.65% 29 0.57% 0.6104 1.01
Alcoholic hepatitis 4 0.08% 11 0.22% 0.0705 3.58
Other hepatitis 5 0.10% 8 0.16% 0.4051 1.65
Pancreatitis 78 1.53% 90 1.77% 0.3505 1.85
Sexually transmitted disease 287 5.63% 285 5.59% 0.9314 0.17
Herpes simplex 43 0.84% 38 0.75% 0.5770 1.10
Burns 16 0.31% 18 0.35% 0.7312 0.68
Trauma 1,278 25.06% 1,285 25.20% 0.8730 0.32
Motor vehicle accidents 8 0.16% 5 0.10% 0.4051 1.65
Pain-related comorbid condition
Cancer 661 12.96% 664 13.02% 0.9296 0.17
Low back pain 1,140 22.36% 1,160 22.75% 0.6356 0.94
Other back/neck disorders 1,040 20.40% 1,056 20.71% 0.6950 0.78
Arthritis 2,170 42.56% 2,196 43.07% 0.6028 1.03
Neuropathic pain 653 12.81% 602 11.81% 0.1242 3.04
Fibromyalgia 157 3.08% 150 2.94% 0.6850 0.80
Headache/migraine 546 10.71% 510 10.00% 0.2420 2.32
Baseline healthcare utilization
Patients with inpatient visits 3,163 62.03% 3,185 62.46% 0.6531 0.89
Patients with outpatient ER visits 2,483 48.70% 2,529 49.60% 0.3622 1.80
Patients with outpatient physician visits 4,810 94.33% 4,836 94.84% 0.2552 2.25
Number of inpatient visits 0.84 0.95 0.85 0.98 0.4869 1.38
Number of outpatient ER visits 0.98 1.60 0.98 1.64 0.9561 0.11
Number of outpatient physician visits 9.77 7.94 9.73 8.07 0.8480 0.38
Baseline healthcare cost
Total costs $28,727 $45,413 $28,219 $50,954 0.5947 1.05
Inpatient cost $13,200 $31,029 $13,084 $34,126 0.8565 0.36
Outpatient ER cost $561 $1,488 $567 $1,601 0.8402 0.40
Outpatient physician visit cost $887 $754 $887 $802 0.9932 0.02
Outpatient pharmacy cost $3,199 $5,324 $3,191 $4,834 0.9289 0.18
Outpatient other costs $10,881 $25,466 $10,568 $29,561 0.5670 1.13
STD, standard deviation; EPO, exclusive provider organization; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; ER, emergency
room; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; PSM, propensity score matching.
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In our study, a lower frequency of prescription opioid
users was found living in the Northeast and Midwest/
North Central United States regions (2.1% and 9.3%,
respectively), and most patients prescribed opioids
resided in the south (86.55%). This study provides
evidence supporting the consistency in geographic opi-
oid prescribing tendencies, as reported in previous
studies. Olsen et al.13 found that U.S. physicians in the
Northeast and Midwest were significantly less likely to
prescribe opioids than those working in the south and
west and that patients in these regions had lower odds of
being prescribed an opioid medication (OR = 0.60 and
0.75).11 In the recent study by McDonald et al.,20
Appalachia, western, and southern states were found to
have the highest opioid prescribing rates. Number of
available physicians was the strongest predictor of
opioid prescription patterns. Unfortunately, the number
of physicians and surgeons was not available in the
database used for this study; therefore, further analysis
will be needed to confirm the risk factors for opioid
prescribing patterns, using alternative data.
This study also examined the frequency and time to
diagnosed opioid abuse by selected diagnosis and
procedure designations. Overall, the frequency of diag-
nosed opioid abuse in patients with common diagnoses/
procedures was low (0.5%); however, the average time
to diagnosed abuse was < 1 year (201 days). As the use
of ICD-9-CM codes could only determine diagnosed
opioid abuse, the generalization of results for undiag-
nosed opioid abusing populations may be invalid. Rates
of prescription opioid abuse in patients from pain clinics
have ranged from 0% to 90%, which demonstrates
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Figure 3. Adjusted cost outcomes for RxOP and NoRxOP cohorts. RxOP, prescription opioid; NoRxOP, no prescription opioid; ED,
emergency department. *P value < 0.0001, **P value < 0.0010.
Table 4. Frequency of Diagnosed Opioid Abuse by Disease and Procedure
Description
Patients with ED/Inpatient Visits Diagnosed Opioid Abusers
Days from First Opioid Prescription to
Opioid Abuse Diagnosis
N (%) N (%) Mean
Total patients 18,819 110 200.65
By disease*
Cardiovascular/metabolic conditions 7,043 (37.42) 43 (39.09) 141.51
Mental health 236 (1.25) 8 (7.27) 201.38
General health/routine screening 2,302 (12.23) 14 (12.73) 260.21
Opioid-related conditions 9 (0.05) 7 (6.36) 14.14
Pain conditions 4,679 (24.86) 56 (50.91) 166.95
By procedure*
Cardiac procedure 129 (0.69) 5 (4.55) 167.40
Orthopedic procedures 36 (0.19) 0
Gynecologic surgery 28 (0.15) 0
General surgery 17 (0.09) 0
Other 0 0
ED, emergency department.
*Within the 3 months before initial opioid prescription in inpatient/ED setting.
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study population heterogeneity and variations in defin-
ing prescription opioid abuse.21
Common cardiovascular/metabolic diseases and gen-
eral health screenings are unlikely causes to initiate
opioid use, and correspondingly, patients in these
categories had low frequencies of diagnosed opioid
abuse. While 2.6% of those with a mental health
condition were later diagnosed with opioid abuse in this
study, the sample size of patients with mental disorders
was small (n = 313), and further research would be
necessary to determine any connections. Although the
sample sizes were small, there was a lack of diagnosed
opioid abuse related to recent clinical procedures,
suggesting that patients prescribed opioid medications
after common clinical procedures are less likely to
become diagnosed opioid abusers.
Due to the nature of the commercial claims database,
the study results only represent the patients who were
continuously insured in the commercial insurance plan.
Uninsured and Medicaid patients, who have been dem-
onstrated to have a high incidence of obtaining prescrip-
tion opioids and percentage of chronic opioid misuse,
were not included in this study. Due to the retrospective
design of the study,22 it is difficult to be certain of causal
relationships. Due to this limitation, only the association
between the variables of interest and the outcomes could
be calculated. Additionally, residual confounding from
unmeasured variables (such as treatment patterns, socio-
economic status, or disease severity) could have affected
associations between various exposure variables and
resulting health outcomes. The presence of a claim for a
filled opioid prescription does not indicate whether the
medication was actually taken as prescribed. Diversion
still exists in situations where patients obtain opioids
outside of the studied healthcare settings, and claims of
diagnosed abuse only capture those patients whose
physicians document their abuse in the claims system.
Therefore, total opioid abuse would likely be underes-
timated. Despite these limitations, the use of a large
claims database and a 4-year observation period in this
study contribute to its nationally representative implica-
tions. This study also uses recent data,which is important
in a population with increasing, rather than stationary,
opioid abuse rates.
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